Literature DB >> 6549149

Characterization of the relaxant effects of vasoactive intestinal peptide (VIP) and PHI on isolated brain arteries.

Y Suzuki, D McMaster, K Lederis, O P Rorstad.   

Abstract

We have studied the vasorelaxant properties of vasoactive intestinal peptide (VIP) using helical strips of bovine, porcine and human brain arteries in vitro. The resting tension of the arterial strips was increased during experiments by prostaglandin F2 alpha or KCl so as to increase the magnitude of the relaxant response to VIP. Arteries supplying different regions of the bovine brain responded potently to VIP with ED50 values of 1.8 nM, 2.3 nM, 6.8 nM and 9.0 nM for the middle, anterior and posterior cerebral arteries and the basilar artery, respectively. The porcine basilar artery and branches of the human middle cerebral artery responded to VIP with ED50 values of 4.2 nM and 1.6 nM, respectively. The homologous neuropeptide, PHI, relaxed the bovine middle cerebral and porcine basilar arteries less potently than did VIP, with ED50 values for PHI being 11 nM and 43 nM, respectively. However, PHI elicited in the two arteries a maximal vasodilatory response of similar magnitude as did VIP. The other homologous peptides, human pancreatic growth hormone releasing factor 1-40 [hpGRF 1-40], secretin, and glucagon, and the VIP fragments, VIP 1-12 and VIP 10-28, were completely inactive. In contrast, VIP, which had been oxidized to VIP-(Met17 sulfoxide) or VIP-(Met17 sulfone), retained full activity. These structure-activity relationships for relaxation of brain arteries are consistent with previous studies of other biological responses to VIP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6549149     DOI: 10.1016/0006-8993(84)91175-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

Review 1.  Neuroprotection in experimental stroke with targeted neurotrophins.

Authors:  Dafang Wu
Journal:  NeuroRx       Date:  2005-01

2.  Localisation of immunoreactive factor VIII, nitric oxide synthase, substance P, endothelin-1 and 5-hydroxytryptamine in human postmortem middle cerebral artery.

Authors:  E Gorelova; A Loesch; P Bodin; L Chadwick; P J Hamlyn; G Burnstock
Journal:  J Anat       Date:  1996-02       Impact factor: 2.610

Review 3.  Parasympathetic innervation of vertebrobasilar arteries: is this a potential clinical target?

Authors:  Eva V L Roloff; Ana M Tomiak-Baquero; Sergey Kasparov; Julian F R Paton
Journal:  J Physiol       Date:  2016-10-05       Impact factor: 5.182

4.  Immunohistochemical localization of vasoactive intestinal peptide (VIP) in the circumventricular organs of the rat.

Authors:  J D Mikkelsen
Journal:  Cell Tissue Res       Date:  1989-02       Impact factor: 5.249

5.  Effects of calcitonin gene-related peptide on canine cerebral artery strips and the in-vivo vertebral blood flow in dogs.

Authors:  I Ikegaki; Y Suzuki; S Satoh; T Asano; M Shibuya; K Sugita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

6.  Vasoactive intestinal peptide stimulates melatonin release from perifused pineal glands of rats.

Authors:  V Simonneaux; A Ouichou; P Pévet
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 7.  Peptides in the mammalian cardiovascular system.

Authors:  J Wharton; S Gulbenkian
Journal:  Experientia       Date:  1987-07-15

8.  Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus.

Authors:  D Currò; P Preziosi; E Ragazzoni; G Ciabattoni
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

9.  Co-release of PHI and VIP in dog stomach by peripheral and central vagal stimulation.

Authors:  T Ohta; S Ito; A Ohga
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

Review 10.  Interventional procedures and future drug therapy for hypertension.

Authors:  Melvin D Lobo; Paul A Sobotka; Atul Pathak
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.